Translation in der Nanomedizin. "Qualitative Indikatoren" der medizinischen Innovationsforschung in der Europäischen Union

点击翻译按钮获取中文摘要

This subproject deals with the future assessment of innovation and innovation research. It qualitatively examines the genesis, usage and consequences of a procedure aiming at evaluating research projects in nanomedicine in Europe on the basis of -- as the actors in this procedure name them -- qualitative indicators, i.e. not-indicators as stated in this project's overarching framework. This procedure has been brought about by the EU platform ETPN (European Technology Platform Nanomedicine) and the EU network ENATRANS (Enabling Nanomedicine Translation). They aim at facilitating and increasing cooperation between science and industry in nanomedicine throughout Europe. This procedure was organised according to the translation assessment (2016-2017) within the framework of a first prototype test phase. This test phase was about building a Translation Advisory Board (TAB) with selected experts from different European countries, who should work on a prototypical qualitative procedure for the evaluation of selected research projects in Europe. At the end of 2017, a systematising test phase has been launched for three years (2018-2021) within the framework of the European Coordination and Support Action NOBEL. Based on the results of the first test phase, the TAB experts construct "qualitative indicators" which they apply to nanomedical research projects selected after an application procedure. This subproject analyses this procedure empirically, starting with and going beyond NOBEL following four steps: a) the methodological basis on which these qualitative indicators are constructed; b) how these indicators take into account the phases of mandatory clinical testing; c) how these indicators take into account the requirements of enterprises/companies/industries in relation to the research projects being evaluated; d) how this qualitative procedure compares to benchmark studies and other quantitative indicators of technological innovation for assessing the sustainability of nanomedicine. These four steps conclude in answering this subproject's framing question, how the relation between experts influences the construction and usage of qualitative indicators in the evaluation procedure and how this affects the sustainability of nanomedicine in Europe.